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Aims Established surgical scores have limitations in delineating risk among candidates for transcatheter aortic valve im-
plantation (TAVI). Assessment of frailty might help to estimate the mortality risk and identify patients likely to
benefit from treatment. The aim of the study was to develop a frailty score to guide the decision for TAVI.
...................................................................................................................................................................................................
Methods
and results
We conducted a prospective observational study in patients >_70 years referred for TAVI during 2011–15. A Heart
Team had declined the patients for open heart surgery due to high risk but accepted them for TAVI. Prior to the
procedure, a geriatric assessment (GA) was performed. Based on this, an 8-element frailty score with a 0–9 (least
frail–most frail) scale was developed. A total of 142 patients, 54% women, mean age 83 (standard deviation 4)
years, with severe and symptomatic aortic stenosis were assessed. All-cause 2 year mortality was 11%. The novel
GA frailty score predicted 2-year mortality in Cox analyses, also when adjusted for age, gender, and logistic
EuroSCORE [hazard ratio (HR) 1.75, 95% confidence interval (CI): 1.28–2.42, P < 0.001]. A receiver operating
characteristic (ROC) curve analysis indicated that a GA frailty score cut-off at >_4 predicted 2-year mortality with a
specificity of 80% (95% CI: 73–86%) and a sensitivity of 60% (95% CI: 36–80%). The area under the curve was 0.81
(95% CI 0.71–0.90).
...................................................................................................................................................................................................
Conclusion A novel 8-element GA frailty score identified gradations in survival in patients declined for open heart surgery.
Patients with higher GA frailty scores had significantly higher 2-year mortality after TAVI.
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.Introduction
The population of older adults is growing, and intrinsic susceptibility
to aortic stenosis is high with this new demographic scenery.
Improved decision making is necessary for the expanding population
of those eligible for transcatheter aortic valve implantation (TAVI).1
Commonly used risk scores for mortality and morbidity in coron-
ary heart surgery, like the Society of Thoracic Surgeons risk score
(STS score) and European System for Cardiac Operative Risk
Evaluation (EuroSCORE), are based on age and comorbidity.2,3
However, by omitting frailty, sensitivity of these scores to predict ad-
verse events in the oldest population is limited.4–6 Frailty, a condition
frequent in older adults, is defined as a state of impaired physiologic
reserve and decreased resistance to stressors which increase the
risk of an adverse outcome.7,8 Frailty status enhances prognostic
sensitivity for patients with multiple heart conditions including
acute coronary disease, stable angina, heart failure, 9–11 and
TAVI.12,13 A recent systematic review confirmed the relationship
between frailty and mortality in the TAVI population, with a more
than doubled risk [hazard ratio (HR) 2.35] of early (<_30 days)
death in frail patients, and a 1.63 HR of later death.14 Although
TAVI has been assessed to be cost-effective compared with med-
ical treatment,15 this is undermined by early mortality after TAVI.
As the population of older adults expands, it is important to select
patients who will benefit most from the intervention to best
justify its expense.16
Both US and European guidelines recommend the use of a Heart
Team in decision making prior to treatment for severe, symptomatic
aortic stenosis.17,18 In addition to the assessments by the interven-
tional cardiologist, cardiac surgeons and imaging specialists, the guide-
lines recommend a frailty assessment to evaluate cognition and
physical function using validated checklists.17 However, it is not
described in detail who should perform and evaluate the frailty as-
sessment and which tools to use.1,17,19 Recently, Afilalo et al.20 dem-
onstrated that the essential frailty toolset (EFT) outperformed other
frailty scores in predicting 1-year mortality in TAVI patients.
Nonetheless the authors emphasized that the EFT is primary a screen
for frailty. Once patients are identified by the EFT, further geriatric as-
sessment (GA) is recommended. This demands a more thorough
clinical evaluation. We developed a novel frailty score that provides
additional information, based on a comprehensive GA. In this study,
we show the utility of this novel GA frailty score to predict 2-year
mortality, showcasing its powerful prognostic value.
Methods
Study design
A prospective, observational cohort study with 2-year follow-up and in-
clusion of elective TAVI patients from 2011 to 2015. The study was
approved by the Regional Committee for Medical Research Ethics (REK
2010/2936-6 and 2013/1310). All participants signed an informed consent
before assessment.
Participants
Patients with severe and symptomatic aortic stenosis accepted for TAVI
were recruited from a tertiary university hospital in Western Norway
serving a population of 1.1 million. All patients were recruited the day be-
fore the procedure and were assessed by a Heart Team consisting of a
cardiac surgeon, an interventional cardiologist and an imaging specialist.
Based on the evaluation, patients were all turned down for open heart
surgery due to comorbidity and/or high EuroSCORE. The recruitment
period lasted from February 2011 to April 2015. From February 2011 to
September 2013, 65 patients >_80 years also participating in a concomi-
tant study of delirium were included.21 From October 2013 to April
2015, 82 patients >_70 years were included (Figure 1). Age was then
adjusted to 70 years as frailty was assessed to be important also in this
younger group. Exclusion criteria were declined consent or inability to
understand and/or speak Norwegian.
Severe aortic stenosis was defined as maximal Doppler velocity across
the aortic valve >_4 m/s, a mean gradient >_40 mmHg or an aortic valve
area <1 cm2 (indexed area <0.6 cm2/m2) and concomitant clinical symp-
toms indicating severe aortic stenosis.
Development of a novel frailty score
The GA frailty score was developed based on a comprehensive GA
which includes cognition, instrumental activity of daily living, nutrition,
physical frailty, comorbidity, and psychological health.22,23 The method
for developing this score is described by Harrell.24 In this method expert
clinicians assign severity points to each condition and sum the points in a
total score. Three geriatricians (A.W.S., A.H.R., and E.S.) and one cardi-
ologist (J.E.N.) independently ranked the clinical severity of signs within
each potentially important domain. The suggestions were sent to the first
author who developed a combined frailty score based on the different
proposals.24 All cut-off values in this combined score were based on pre-
vious studies.13,22 The researchers then agreed on the GA frailty score, a
0–9 point numeric scale with 8 validated geriatric variables (Table 1). The
score was finalized before the statistical analysis were performed.
Figure 1 Patient recruitment flowchart.
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Measurements
Novel frailty score
Baseline data were collected by L.S.P.E. and E.S. All baseline examinations
were performed the day before the procedure. Cognition was assessed
by the Mini Mental Status Examination (MMSE).25 It has a range from 0 to
30, with higher scores indicating better cognition. Different cut-offs are
reported, and we chose a weighted score with one point for possible
cognitive impairment/mild dementia and two points for probable
dementia.13,26
Instrumental activities of daily living was measured by Nottingham
Extended Activities of Daily Living scale (NEADL),27 a 22-item question-
naire assessing mobility, kitchen, domestic, and leisure activities. Each
item has a score from 0 to 3, and the items are added to a total score
from 0 to 66, with a higher score indicating better functioning. A cut-off
<_43 suggests that the patient is dependent, and studies have shown that
this predicts complications and mortality after elective surgery in older
patients.28,29
Nutrition was assessed by the body mass index (BMI) and the weight
question of modified Study of Osteoporotic Fractures index. The cut-off
value for BMI was based on the nutritional risk screening 2002, a screen-
ing instrument for nutritional risk.30
Physical frailty was assessed by a modified version (patients self-
reported weight loss past year, not measured as in the original index)
of the Study of Osteoporotic Fractures Index (mSOF index).31 This
validated index has a maximum of three points: (i) One point if the pa-
tient has >5% weight loss the previous year (Since, we only had base-
line characteristics, the patients were given one point if answering yes
to the question ‘have you lost weight during the past year’), (ii) one
point if the patient is unable to rise from a chair without using their
arms (This was tested by L.S.P.E./E.S., not reported by the patients.),
and (iii) one point if the patient answers no to the question ‘Do you
feel full of energy?’.
Comorbidity was assessed by Charlson comorbidity index. This is a
weighted index based both on the numbers of diseases and the serious-
ness of each disease. A score of 1 is assigned for myocardial infarction,
congestive heart failure, dementia, etc., while the highest score of 6 is
given to metastatic solid tumours and AIDS. In the original paper describ-
ing the index, Charlson et al.32 recommends a high cut-off of 2 or 3 if the
mortality in the disease under study is high, and we chose a cut-off >_3.
Psychological health was assessed by the Hospital Anxiety and
Depression Scale (HADS),33 with seven questions on anxiety and seven
on depression. Each question ranges from 0 to 3. Summing up the anxiety
and depression subscales, we get total HADS, of which a cut-off >_15 was
used to identify symptoms of anxiety and/or depression.33,34
The modified essential frailty toolset
The Essential Frailty Toolset (EFT) is a brief four-item (chair rise,
cognition, haemoglobin, and serum albumin) frailty scale that predicts
morbidity and mortality after TAVI.20 Afilalo recommends applying this
scale as a screening tool.20 In this study, we aimed to compare the GA
frailty score to the EFT.
However, for the first 62 patients in our study, we only had informa-
tion on success/failure of chair rise, not on the number of seconds it took
to complete the chair rises. Therefore, when calculating the EFT for these
patients, we assigned 0 points if they completed five sit-to-stand repeti-
tions without using arms (chair rises) and 2 points if they failed to com-
plete all five chair rises. We refer to this modified methodology for the
EFT as the modified Essential Frailty Toolset (mEFT). This might give
some patients one point lower total score (i.e. the patients who used
>_15 s to perform chair rise). For three patients, we missed serum albumin
values, and the mEFT was thus calculated for 139 patients.
Follow-up measurements
Two-year all-cause mortality has been stated as a clinically relevant out-
come for TAVI candidates and was the primary outcome of this study.1
The Valve Academic Research Consortium-2 (VARC 2) consensus docu-
ment6 recommends the use of composite endpoints after TAVI, and we
report this for the first 6 months.
Power analysis
The initial power analysis was based on categorizing the patients into
three groups, a fit group, an intermediate group and a frail group, with
25% in the frail group.22,35,36 To achieve a power of 80% with a 5% level
of significance, power calculations showed that we needed a total of 140
patients. To account for dropouts, we included 5% more, a total of 147
patients. In order to make the frailty score more applicable in clinical
practice, we ultimately dichotomized it into frail and non-frail (fit and
intermediate). In addition, we analysed frailty as a continuous score,
which increases the statistical power.
Statistical analyses
We present the data as means and standard deviations (SDs), counts and
percentages, or proportions and Hazard Ratios (HRs) with 95% confi-
dence intervals (CIs), as appropriate. To assess whether the new frailty
score could predict mortality within 2 years, and also when adjusted for
other common predictors, we fitted Cox regression models with Firth’s
correction. Firth’s correction provides reduced bias when there are few
events (deaths) compared with the number of predictors. The regression
models included frailty score as a continuous predictor (unadjusted
model/trend test), or frailty score, age, gender, and logistic EuroSCORE
as predictors (adjusted model). We also fit a similar adjusted model with
frailty score as a dichotomized variable. We present time to death strati-
fied by frailty score (continuous or dichotomized ) using Kaplan–Meier
plots.
The Receiver Operating Characteristic (ROC) curve37 was examined
to find cut-off values for the dichotomized GA frailty score. We reported
the Area Under the Curve (AUC) as a summary measure. We found two
.................................................................................................
Table 1 Geriatric assessment tools used in the novel
frailty score, along with the corresponding scoring
scheme
Domain Cut-off Points
Cognition MMSE >_27 0
MMSE 20–26 1
MMSE <20 2
Instrumental activity of living NEADL <_43 1
Nutrition BMI <20.5 1
Energy level SOF index Low energy 1
Weight loss SOF indexa Weight loss 1
Limb strength SOF index Chair stand (not able) 1
Comorbidity Charlson comorbidity index >_3 1
Psychological factors HADS (total score) >_ 15 1
Total Maximum score 9
The total score is calculated by adding the different domain scores.
BMI, body mass index; HADS, Hospital Anxiety and Depression Scale; MMSE,
Mini Mental Status Examination; NEADL, Nottingham Extended Activity of Daily
Living Scale; SOF Study of Osteoporotic Fractures index.
aModified from the original SOF; see ‘Measurements’ section for details.
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cut-off values with an estimated high sensitivity and specificity, and chose
the one (>_4) emphasizing specificity over sensitivity. Confidence intervals
for the sensitivity and specificity were calculated using the Wilson (score)
method.38
Some patients had missing data for a few of the questions in the HADS
and NEADL questionnaires. Where it was unambiguous on which side of
the cut-off the total score would fall on, we used the data for these
patients; otherwise, the patients were excluded. For one secondary ana-
lysis (based on the mEFT frailty scale), there were additional missing data.
For all analyses, we report the number of observations used.
Statistical analyses were performed using IBM SPSS Statistics 24 and R
version 3.5.0.39 Cox regression with Firth’s correction was performed
using R ‘coxphf’ package40 version 1.13, and the ROC and AUC calcula-
tions were performed using the R ‘pROC’ package version 1.12.1.41
Results
Baseline data
General characteristics
A total of 147 patients with severe and symptomatic aortic stenosis
were included. Of these, 142 patients had enough data so that the
frailty score could be computed (Figure 1). Of the 142 patients, 54%
were women, mean age was 83 years (SD 4), five patients were less
than 75 years old and three patients were 90 years or older. The old-
est patient in the study was 95 years old. More than half of the
patients lived with their spouse.
Geriatric characteristics
More than half of the patients (56%) did not have significant cognitive
disturbance, a MMSE of 27 or higher. The others (44%) had possible
cognitive impairment, but for most of them (89%) probably mild cog-
nitive impairment or mild dementia (MMSE 20–26). Most patients
(82%) had a NEADL score above 43, suggesting they were independ-
ent in activities of daily living. Few patients (13%) had low BMI (below
20.5 kg/m2); however, 52 (37%) patients had a reported weight loss
during the last year. Sixty-one (43%) of the patients had a high score
of >_3 on the Charlson comorbidity scale.
Cardiovascular characteristics
Almost all patients 127/135 (missing data on seven patients) had an
indexed aortic valve area below 0.6 cm2/m2. Logistic EuroSCORE
was below 10 in 18% and over 20 in 30% of the patients. Half of the
patients had New York Heart Association III or IV at the time of the
procedure (Table 2).
Follow-up
No patients were lost to follow-up.
Mortality and morbidity
Fifteen patients (11%) had died within 2 years, 11 of cardiovascular
causes and four of non-cardiovascular causes. There was a high de-
gree of early device success, with 141/142 (99.3%) valves in the cor-
rect position with good valve function. Early (<_30 days) mortality was
seen in four patients (2.8%). Moderate to severe prosthetic valve re-
gurgitation and stroke occurred within 6 months in 12.7% and 4.8%
of the patients, respectively (Table 3).
.................................................................................................
Table 2 Patient baseline characteristics (n5 142)
Mean or
count
SD or
(proportion)
Characteristics
Age, years 83.4 4.0
Women 76 (54%)
Living alone 60 (42%)
Education
Primary school 88 (62%)
High school 33 (23%)
University 21 (15%)
Geriatric characteristics
Cognition
MMSE 26.3 3.3
MMSE >_27 80 (56%)
MMSE 20–26 55 (39%)
MMSE <20 7 (5%)
Activities of daily living
NEADL <_43 121 (82%)
Nutrition
BMI 25.0 3.9
BMI <20.5 19 (13%)
SOF index
Weight lossa 52 (37%)
Low energy 58 (41%)
Unable to chair stand 42 (30%)
Comorbidity
Charlson comorbidity index 2.53 1.3
Charlson comorbidity index >_3 61 (43%)
Psychological factors
HADS >_15 17 (12%)
Cardiovascular characteristics
Logistic EuroSCORE 17 8.7
Aortic valve area index, cm2/m2 b 0.4 0.12
Mean aortic valve gradient, mmHgc 47.6 14.4
Left ventricular ejection fraction 56.4 11
NYHA >_III 67/134 (50%)
Previous myocardial infarction 34 (24%)
CABG 31 (22%)
Permanent pacemaker 12 (9%)
Atrial fibrillation 45 (32%)
Pulmonary hypertension 45/139 (32%)
Cerebral vascular disease 16 (11%)
Comorbidity
COPD 31 (22%)
Kidney failure; creatinine >177 mmol/Ld 5 (4%)
MMSE, Mini Mental Status Examination; NEADL, Nottingham Extended Activities
of Daily Living Scale; BMI, Body Mass Index; SOF Index, Study of Osteoporotic
Fractures Index; HADS, Hospital Anxiety and Depression Scale; NYHA, New
York Heart Association Functional Classification of Heart Failure, Range From I-
IV, Most Severe Symptoms at IV; CABG, Coronary Artery Bypass Grafting;
COPD, Chronic Obstructive Pulmonary Disease.
aModified from the original SOF index; see ‘Measurements’ section for details.
bMissing data on seven patients.
cMissing data on two patients.
dAs reported in the PARTNER study; creatinine >2 mg/dL (177 mmol/L).1
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Frailty and mortality
The distribution of frailty scores and the corresponding 2-year mor-
tality is shown in Table 5. Based on the dichotomized GA frailty score,
34 patients (24%) were characterized as frail (score >_4).
The Cox analyses showed that the continuous GA frailty score
predicted mortality within 2 years, with an estimated HR of 1.79 (95%
CI: 1.34–2.36, P< 0.001), i.e. an estimated 79% increase in hazard for a
unit increase in GA frailty score. This predictive power also remained
(HR = 1.75, 95% CI: 1.28–2.42, P< 0.001) when adjusting for age, gen-
der, and logistic EuroSCORE (Table 4). A test of the proportional haz-
ard assumption did not find any problems with the model (P= 0.77).
The corresponding results for the dichotomous GA frailty score
were HR = 5.35 (95% CI: 1.99–15.3, P= 0.001) (unadjusted) and HR
= 4.91 (95% CI: 1.79–14.2, P= 0.002) (adjusted).
The ROC curve (Figure 2) illustrates that a frailty score cut-off
at >_4 predicts 2 year mortality with a specificity of 80% (95% CI:
73–86%) and a sensitivity of 60% (95% CI: 36–80%). The AUC was
0.81 (95% CI: 0.71–0.90).
None of the patients with a frailty score of 0 or 1 were dead after
2 years, and none of the patients had a frailty score of 8 or 9. In gen-
eral, the higher the frailty score, the higher the risk of dying within 2
years (Table 5).
When adjusting for mEFT along with age, gender, and logistic
EuroSCORE, the continuous GA frailty score were no longer a
statistically significant predictor (HR = 1.36, 95% CI: 0.87–2.21,
P= 0.18, n= 139), and neither were any of the other variables
(including mEFT).
Discussion
In this prospective observational study, we found that a novel GA
frailty score could predict 2-year all-cause mortality in TAVI
....................................................................................................................................................................................................................
Table 3 Composite endpoints according to Valve Academic Research Consortium-2 consensus documenta criteria
Total (N 5 142) Percent
Device success
Absence of immediate procedural mortalityb 142 100
Correct positioning 141 99.3
Intended performance of the prosthetic heart valvec 141 99.3
No moderate or severe prosthetic valve regurgitationd 135 95.1
Early safety(at 30 days)
All-cause mortality 4 2.8
All stroke(disabling or non-disabling) in hospitale 4 2.8
Life-threatening or disabling bleeding 8 5.6
Acute kidney injury Stage 2 or 3f 3 2.1
Coronary artery obstruction requiring intervention 1 0.7
Major vascular complication 6 4.2
Valve-related dysfunction requiring intervention 1 0.7
Clinical efficacy(30 days–6 months)
All-cause mortality 6 4.2
All stroke(disabling or non-disabling) 3 2.1
Requiring hospitalizations for valve-related symptoms or worsening congestive heart failure 15 10.6
NYHA class III or IVg 9/136 6.6
Time-related valve safety
Structural valve deterioration
Valve-related dysfunction (mean aortic valve gradient >_20 mmHg) and/ or moderate or severe
prosthetic valve regurgitationh
18/141 12.7
Requiring repeat procedure (TAVI or SAVR) 1 0.7
Prosthetic valve endocarditis 1 0.7
Trombo-embolic events (e.g. stroke) 7 4.8
VARC bleeding (life threatening/disabling bleeding or major bleeding) and unless clearly unrelated
to valve therapy (e.g. trauma)
28 19.7
SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation; NYHA New York Heart Association.
aThe Valve Academic Research Consortium (VARC)-2 consensus document (see references).
bImmediate or consequent death <_72 h post-procedure.
cNo prosthesis patient mismatch and mean aortic valve gradient <20 mmHg or peak velocity <3 m/s.
dAfter TAVI procedure at index hospitalization.
eAssessment of stroke at index. All strokes verified by imaging (CT or MRI).
fEvaluation of acute kidney injury is based on serum creatinine, we miss data on urine output.
gNew York Heart Association (NYHA), missing data on six patients.
hFollow-up at 6 months, missing data on one patient.
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patients declined for open heart surgery by a Heart Team. After 2
years, there were no deaths in the cohort with very low (0 or 1)
frailty score.
Standard risk scores like EuroSCORE and STS score are insuffi-
cient for predicting adverse events in the older adult,11,13,42 and a
frailty assessment adds information which increases predictability.
There is an ongoing discussion regarding the definition of frailty and
whether to include cognition, psychological factors, and comorbid-
ity.43 The GA frailty score was developed to provide information for
a better decision making prior to TAVI. This study adds to previous
work highlighting the need for a more thorough evaluation of the in-
dividual patient based on a comprehensive GA. This can provide sig-
nificant decision-making support for the interventional cardiologist or
surgeon. The purpose of the score is not to screen all TAVI candi-
dates, as this will be too time-consuming. Rather it should be used in
patients in whom a simpler screening44 has revealed potential
obstacles for TAVI. In this setting, an assessment solely on physical
frailty would not be sufficient, in part due to decline in physical
performance related to severe aortic stenosis. An approach with an
initial basic screening for frailty and a selective thorough assessment
by a geriatrician has been advocated.44,45
Patients categorized as frail might still be eligible for TAVI. All
patients should be involved in a shared decision process regarding
their treatment, but for patients where there is doubt whether the
procedure is beneficial, it is especially important. Previous studies
have underlined the importance of exploring patients’ perspec-
tives.46,47 Asking the question ‘What do you hope to accomplish by
having your valve repaired?’ might capture what is most important to
patients.48 The decision to offer TAVI should in the end be made by
the interventional cardiologist or cardiac surgeon performing TAVI,
based on an analysis of benefit vs. risk, taking into account symptoms,
comorbidity, patient perspective, procedural risk, and frailty. We sug-
gest the geriatrician to be an important collaborator in this analysis. If
TAVI is offered despite frailty, the treatment team should be pre-
pared for a higher risk of complications, including delirium.21 Ideally,
detecting frailty should lead to additional pre-, per-, and post-opera-
tive support.11 The GA frailty score provides delineation of specific
aspects of frailty that can be addressed (e.g. nutritional supply if
undernourished, treatment for depression).49,50 We do not have
enough evidence to recommend specific exercise before TAVI in
order to improve frailty status.
This study confirms the clinical relevance of frailty assessment
prior to TAVI.12,13,17 The GA frailty score evaluating cognition, in-
dependence in daily life, nutrition, physical frailty, comorbidity,
and psychological health, give a thorough and comprehensive as-
sessment of the patient. A high GA frailty score >_4 indicates a
reduced 2-year survival (Figure 3). However, we do not advocate
a strict cut-off where TAVI is not offered. Knowledge of the (0–9
based) GA frailty score should lead to a careful final evaluation by
the TAVI team, and should involve weighting frailty, technical
challenges, exploring patient preferences, and symptom burden
before offering TAVI. The geriatrician can contribute to the heart
team as a frailty expert.
.................................................................................................
Table 5 Distribution of geriatric assessment frailty
score and mortality within each frailty score (n5 142)
Frailty
score
Count Prop.
(%)
Cum.
prop. (%)
Deathsa Mortalitya
(%)
0 15 11 11 0 0
1 26 18 29 0 0
2 39 27 56 2 5
3 28 20 76 4 14
4 20 14 90 4 20
5 10 7 97 3 30
6 2 1 99 2 100
7 2 1 100 0 0
8 0 0 100 — —
9 0 0 100 — —
Cum., cumulative; Prop., proportion.
aDeaths within 2 years after TAVI.
Figure 2 Receiver operator characteristics curve for geriatric as-
sessment frailty score (0–9) and 2 year mortality (n= 142). The area
under the curve is 0.81 (95% confidence interval: 0.71–0.90).
................................... ...................................
.................................................................................................
Table 4 Cox regression (with Firth’s correction)
(n5 142)
Unadjusted Adjusted
HR 95% CI P-value HR 95% CI P-value
Age, years 1.16 1.00–1.37 0.04 1.16 1.01–1.37 0.04
Male gender 1.01 0.37–2.71 0.99 2.14 0.68–6.93 0.19
Logistic
EuroSCORE
1.06 1.01–1.11 0.02 1.04 0.99–1.08 0.13
GA frailty score 1.79 1.34–2.36 0.001 1.75 1.28–2.42 <0.001
CI, confidence interval; HR, hazard ratio.
Hazard ratio estimates (with 95% confidence intervals) for death within 2 years
of transcatheter aortic valve implantation. The hazard ratios show the increase in
hazard for a unit increase in age (years), logistic EuroSCORE and/or GA frailty
score, and for males compared with females.
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Strengths of the study
This is a prospective study, with potentially fewer sources of bias
and higher quality of data than a retrospective study would have.
In Norway, deaths of all patients are automatically registered
in the patients’ electronic journal. Our primary outcome is there-
fore complete. We also have high completeness in the rest of our
data, and importantly, no patients are lost to follow-up for the
primary endpoint. The variables included in the GA frailty score
were determined before the statistical analysis, eliminating the
risks associated with a purely data-driven analysis. Finally, our
risk score was reliable in patients already excluded from surgery
due to comorbidity.
Limitations of the study
Survival with benefit after 2 years is advocated as a relevant clinical
endpoint, and it would have strengthened the study if we also
assessed quality of life in the patient 2 years after the procedure.1
However, there are limitations to soft endpoints, and in order to sim-
plify the interpretation of the frailty score, we chose to focus mainly
on prediction of mortality. Some items were self-reported and not
performance based, introducing some subjectivity to the index; how-
ever, previous studies have showed for all the selected self-report
items to be markers of frailty.7,31 This is a single-centre study, and the
results might not be transferable to any other centre, although they
are probably comparable to other European centres of the same
size. The study population changed during the study. Initially, inclusion
consisted of patients >_80 years, but was later expanded to include all
patients >_70 years. This was partly due to a shift in the general TAVI
population, but also a growing awareness that frailty is a complex
phenomenon where age is only one contributing factor.7 The partial
lack of data used in calculating the EFT score reduces the precision of
the score somewhat. And finally, the small sample size (especially the
few number of deaths) is a limitation, particularly for calculating the
sensitivity of the dichotomized frailty score in predicting 2-year mor-
tality. Before recommending the GA frailty scale, it needs to be vali-
dated in an independent population.
Conclusions
In patients declined for open heart surgery, an 8-element frailty score
based upon GA can identify patients less likely to benefit from TAVI.
Patients with a frailty score >_4 had significantly higher 2-year mortal-
ity. We believe the novel GA frailty score has clinical relevance and
may be a useful tool for heart teams in decision making for TAVI.
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